Skip to main content

Table 1. Characteristics of the 197 patients with diffuse large B-cell lymphoma (DLBCL)

From: Use of subsequent PET/CT in diffuse large B-cell lymphoma patients in complete remission following primary therapy

Variate

Number of patients [cases (%)]

Sex

 

  Male

119 (60.4)

  Female

78 (39.6)

Age ⩾ 60 years

48 (24.4)

Ann Arbor stage

 

  I

31 (15.7)

  II

49 (24.9)

  III

42 (21.3)

  IV

75 (38.1)

IPI

 

  Low (0 or 1)

91 (46.2)

  Low/intermediate (2)

36 (18.3)

  High/intermediate (3)

15 (22.8)

  High (4 or 5)

25 (12.7)

Chemotherapy

 

  R-CHOP-14

28 (14.2)

  R-CHOP-21

169 (85.8)

  1. IPI, International Prognostic Index; R, rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP-14, R-CHOP regimen administered with a 14-day interval; R-CHOP-21, R-CHOP regimen administered with a 21-day interval